Rezolute (RZLT) had the highest return in 2013 by a US stock in the Biotechnology Industry, returning 183,291%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Rezolute (RZLT) | 2013 | 183,291% |
Aurinia Pharmaceuticals (AUPH) | 2013 | 5,088.91% |
Enveric Biosciences (ENVB) | 2013 | 669.51% |
Inovio Pharmaceuticals (INO) | 2013 | 468.63% |
Edesa Biotech (EDSA) | 2013 | 450% |
Puma Biotechnology (PBYI) | 2013 | 447.2% |
ACADIA Pharmaceuticals (ACAD) | 2013 | 422.8% |
Arrowhead Pharmaceuticals (ARWR) | 2013 | 402.31% |
BioCryst Pharmaceuticals (BCRX) | 2013 | 377.99% |
Catalyst Pharmaceuticals (CPRX) | 2013 | 348.28% |
VivoSim Labs (VIVS) | 2013 | 313.06% |
Galectin Therapeutics (GALT) | 2013 | 294.15% |
Anika Therapeutics (ANIK) | 2013 | 277.08% |
Ionis Pharmaceuticals (IONS) | 2013 | 274.79% |
Prothena (PRTA) | 2013 | 253.6% |
Celldex Therapeutics (CLDX) | 2013 | 251.38% |
Alnylam Pharmaceuticals (ALNY) | 2013 | 239.31% |
Geron (GERN) | 2013 | 229.19% |
Vanda Pharmaceuticals (VNDA) | 2013 | 228.31% |
Alterity Therapeutics (ATHE) | 2013 | 217.19% |
Sellas Life Sciences (SLS) | 2013 | 210% |
Incyte (INCY) | 2013 | 202.81% |
NanoViricides (NNVC) | 2013 | 191.79% |
Eterna Therapeutics (ERNA) | 2013 | 186.36% |
Genmab A-S (GMAB) | 2013 | 179.57% |